Evaluating the CroíValve DUO System for Tricuspid Regurgitation

A European Feasibility Study of the CroíValve DUO Transcatheter Tricuspid Coaptation Valve System in Patients with Tricuspid Regurgitation

This study is testing a new heart valve system to see if it can help people with severe tricuspid regurgitation who still have symptoms despite taking medication.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 10 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: CroiValve Limited (Industry-sponsored)
• Locations: 3 sites (Gdańsk and 2 other locations)
• Trial ID: NCT05296148 on ClinicalTrials.gov

What this trial studies

This is a prospective, multicentre, non-randomized single-arm feasibility study aimed at assessing the safety and performance of the CroíValve DUO Transcatheter Tricuspid Coaptation Valve System in patients suffering from severe Tricuspid Regurgitation. The study will involve patients who are symptomatic despite medical therapy and have been evaluated by a Heart Team for anatomical suitability. Participants will undergo transcatheter tricuspid valve implantation as the primary intervention.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older with severe Tricuspid Regurgitation who are symptomatic and on stable medical therapy.

Not a fit: Patients who have previously undergone tricuspid valve repair or replacement may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a new treatment option for patients with severe Tricuspid Regurgitation who are not responding to conventional medical therapy.

How similar studies have performed: While this approach is innovative, it is part of a growing field of transcatheter interventions for heart valve diseases, and similar studies have shown promise in other valve treatments.

Eligibility criteria

Inclusion Criteria:

1. Presence of severe Tricuspid Regurgitation per American Society of Echocardiography (ASE) Criteria determined by Echo Core Lab assessment of a qualifying Transthoracic Echocardiogram (TTE).
2. Subject is symptomatic despite medical therapy (NYHA Functional Class II or higher)
3. Subject is on stable medical therapy as assessed by the Heart Team
4. The patient's anatomy is suitable in the judgment of the Investigational Site Heart Team and the Patient Screening Committee.
5. Age ≥18 years
6. The patient or the legal representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent on a form, as approved by the EC of the respective clinical site.

Exclusion Criteria:

1. Subject is currently participating in another clinical investigation that could affect the outcome of this trial
2. Transesophageal echocardiography (TEE) is contraindicated or unsuccessful
3. Previous tricuspid valve repair, replacement or transcatheter tricuspid intervention
4. Moderate to severe tricuspid valve stenosis
5. Severe aortic, mitral and/or pulmonic valve stenosis and/or regurgitation
6. Significant comorbid factors which places the subject at prohibitive risk for surgical repair in the judgment of the Investigational Site Heart Team and the Patient Screening Committee
7. Need for concomitant surgical or interventional procedure known at time of screening (e.g., CABG, Atrial Septal Defect (ASD) repair).
8. Ejection Fraction (EF) \<30% within 45 days of the implant procedure
9. Echocardiographic or CT evidence of intracardiac mass, thrombus or vegetation
10. Patient has Systolic Pulmonary Pressure (sPAP) \>60 mm Hg
11. Severe hemodynamic instability: cardiogenic shock or the need for inotropic support or Intra-Aortic Balloon Pump (IABP) or other percutaneous ventricular assist devices
12. Severe respiratory instability: Severe COPD or continuous use of home oxygen or has FEV1 \<50% of predicted
13. Severe right ventricular dysfunction as determined by the Echo Core Lab
14. Untreated clinically significant coronary artery disease requiring revascularization surgical or interventional PCI
15. Stroke or transient ischemic event within 90 days prior to the implant procedure
16. Untreated severe symptomatic carotid stenosis (\>70% by ultrasound)
17. Acute myocardial infarction within 30 days before the index procedure
18. Renal insufficiency (eGFR\<25 ml/min)
19. Active endocarditis within 6 months of the implant procedure
20. Pulmonary embolism within the last 6 months
21. Any surgical, interventional, or transcatheter procedure within 30 days prior to the index procedure
22. Patient has an SVC dimension/anatomy is not suitable for device implantation (i.e., extremely tortuous, heavily calcified, aneurysmal)
23. Hypertrophic cardiomyopathy, restrictive cardiomyopathy or constrictive pericarditis
24. Life expectancy \<1 year
25. Active infections requiring current antibiotic therapy
26. Known severe liver disease
27. Prior heart or lung transplant
28. Known active peptic ulcer or active GI bleed
29. Unable to take anticoagulant therapy
30. Known patient is actively abusing drugs
31. Subjects who are pregnant or planning to become pregnant
32. Any condition making it unlikely the subject will be able to complete all protocol procedures (including compliance with guideline-directed medical therapy and immobility that would prevent completion of 6MWT), follow-up visits, or impact the scientific soundness of the clinical investigation result
33. Any known major coagulation abnormalities, thrombocytopenia, platelets \<50,0000/ml or anemia Hb \<9g/dl
34. Any known sensitivities or allergies to contrast and/or the device materials, including nickel and titanium
35. BMI \>50kg/m2
36. Transvalvular implanted pacemaker or ICD lead is present

Where this trial is running

Gdańsk and 2 other locations

• Uniwersyteckie Centrum Kliniczne GUMed — Gdańsk, Poland (Recruiting)
• Górnośląskie Centrum Medyczne im. Prof. Leszka Gieca — Katowice, Poland (Recruiting)
• Narodowy Instytut Kardiologii im. Stefana kardynała Wyszyńskiego — Warsaw, Poland (Recruiting)

Study contacts

• Study coordinator: Helen Scotch

Conditions Tricuspid Regurgitation